Abstract
We describe a pediatric cystic fibrosis patient who developed a pulmonary exacerbation due to two multidrug-resistant (MDR) Pseudomonas aeruginosa isolates. In addition to these MDR organisms, the case was further complicated by β-lactam allergy. Despite the MDR phenotype, both isolates were susceptible to an antimicrobial combination.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
MeSH terms
-
Adolescent
-
Amikacin / therapeutic use
-
Anti-Bacterial Agents / adverse effects
-
Anti-Bacterial Agents / therapeutic use*
-
Ciprofloxacin / therapeutic use
-
Cystic Fibrosis / complications*
-
Cystic Fibrosis / microbiology
-
Drug Hypersensitivity / etiology
-
Drug Resistance, Multiple, Bacterial / drug effects*
-
Drug Therapy, Combination
-
Female
-
Humans
-
Microbial Sensitivity Tests
-
Penicillanic Acid / analogs & derivatives
-
Penicillanic Acid / therapeutic use
-
Pseudomonas Infections / drug therapy*
-
Pseudomonas Infections / microbiology
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / pathogenicity
-
Tazobactam
-
beta-Lactams / adverse effects
Substances
-
Anti-Bacterial Agents
-
beta-Lactams
-
Ciprofloxacin
-
Amikacin
-
Penicillanic Acid
-
Tazobactam